Serina Non Currrent Assets Other from 2010 to 2024
| SER Stock | 4.79 0.64 15.42% |
Non Currrent Assets Other | First Reported 2010-12-31 | Previous Quarter 607 K | Current Value 697.8 K | Quarterly Volatility 906.1 K |
Check Serina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Serina Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 124.5 K, Total Revenue of 134.9 K or Other Operating Expenses of 6.8 M, as well as many indicators such as Price To Sales Ratio of 148, Dividend Yield of 0.0 or PTB Ratio of 2.58. Serina financial statements analysis is a perfect complement when working with Serina Therapeutics Valuation or Volatility modules.
Serina | Non Currrent Assets Other |
Latest Serina Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Serina Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Serina Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Serina Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Serina Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 1,694,451 | |
| Geometric Mean | 1,125,763 | |
| Coefficient Of Variation | 53.47 | |
| Mean Deviation | 756,732 | |
| Median | 2,262,000 | |
| Standard Deviation | 906,082 | |
| Sample Variance | 821B | |
| Range | 2.3M | |
| R-Value | (0.77) | |
| Mean Square Error | 359.6B | |
| R-Squared | 0.59 | |
| Significance | 0.0008 | |
| Slope | (156,063) | |
| Total Sum of Squares | 11.5T |
Serina Non Currrent Assets Other History
About Serina Therapeutics Financial Statements
Serina Therapeutics shareholders use historical fundamental indicators, such as Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Serina Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Serina Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Serina Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 607 K | 697.8 K |
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.